High-yield points
- RE = immune-mediated, unihemispheric, progressive. Atrophy, deficits and drug-resistant focal seizures (often epilepsia partialis continua), mostly in children .
- MRI: progressive unilateral perisylvian and insular atrophy with caudate head atrophy (see caveats).
- Tacrolimus or IVIG may slow early disease (compared with historical controls) but does not rescue established drug-resistant epilepsy .
- Hemispherotomy is definitive: 68% seizure-free, with function largely preserved, including in left-hemisphere cases .
Landmark papers
- Bien et al., Epilepsia 2013: the first (and still the only) randomized trial in Rasmussen encephalitis (16 patients with recent-onset disease, tacrolimus or IVIG). Both groups did better than historical controls and neither drug was better; no patient with already refractory epilepsy responded .
Rasmussen encephalitis (RE) is a rare, severe, immune-mediated disease of one hemisphere. It causes three things together :
- progressive unilateral hemispheric atrophy;
- progressive neurological deficits;
- intractable focal seizures, often epilepsia partialis continua.
Hemispheric disconnection is the treatment of choice for established disease. The difficult decision is when to operate .
Epidemiology and pathogenesis
- Incidence: about 2.4 cases per 10 million people aged 18 or under per year (Germany) .
- Typical onset in childhood. In a surgical series, the mean age at seizure onset was 6 years .
- Pathogenesis: a T-cell-mediated (cytotoxic) attack on one hemisphere. The trigger is unknown ; see caveats.
Diagnosis (European consensus criteria)
- Formal criteria combine clinical, EEG, MRI and, when needed, histopathological features .
- Typical features (see caveats):
- focal seizures, with or without epilepsia partialis continua;
- unilateral cortical deficits (hemiparesis, hemianopia, aphasia);
- unihemispheric EEG slowing and epileptiform activity;
- MRI: unilateral focal cortical atrophy with T2/FLAIR signal change, often perisylvian and insular, and caudate head atrophy, progressing on serial scans.
- Brain biopsy is reserved for uncertain cases:
- T-cell-dominated encephalitis;
- microglial nodules;
- neuronal loss.
Treatment
Immunotherapy
- The only randomized trial (Germany) :
- Who: 16 patients with recent-onset RE, randomized to tacrolimus or IVIG.
- Result: both groups "survived" longer than historical controls before losing function or hemispheric volume. Neither drug was better.
- Epilepsy: no immunotreated patient developed intractable epilepsy, but no patient whose epilepsy was already refractory responded.
- Safety: two tacrolimus patients had serious adverse events.
- The dilemma: immunotherapy may "arrest" a child with drug-resistant epilepsy whose function is too good to offer hemispherectomy .
- Where it fits: early disease, or a dominant hemisphere with preserved function, to slow progression and buy time ; see caveats.
Hemispheric surgery
- The definitive treatment for drug-resistant RE .
- Brazilian series (44 children, 1995–2020) :
- Before surgery:
- mean age at surgery 9 years, after 2.5 years of epilepsy;
- abnormal intellect in 86% and hemiparesis in 90%;
- histology confirmed RE in 95%.
- Seizure outcome: 68% seizure-free; 70% Engel I–II.
- Function:
- cognition unchanged in 64%;
- gross motor function unchanged in 54%;
- 74% had functional hand use.
- Recommendation: hemispheric surgery should be offered to children with RE, even when the left hemisphere is involved.
- Timing:
- Earlier surgery gives more chance of language transfer and avoids prolonged uncontrolled seizures.
- Later surgery may cost less new function, because a dense hemiparesis has usually already developed (see caveats).
- The decision is individual and multidisciplinary.
- Technique: functional hemispherotomy (vertical or peri-insular) or hemispherectomy (see Hemispherectomy).
Related topics
- Hemispherectomy: techniques and outcomes of hemispheric disconnection.
- Epilepsy Surgery Overview: surgical context.
- Encephalitis: Neurosurgical Implications: acute infectious and autoimmune encephalitis.
- Hemispherectomy and Hemispherotomy: Procedure: step-by-step procedure.
References
- Bien CG, Granata T, Antozzi C, et al. Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: a European consensus statement. Brain 2005;128(Pt 3):454–471. doi:10.1093/brain/awh415. PMID 15689357. verified
- Bien CG, Tiemeier H, Sassen R, et al. Rasmussen encephalitis: incidence and course under randomized therapy with tacrolimus or intravenous immunoglobulins. Epilepsia 2013;54(3):543–550. doi:10.1111/epi.12042. PMID 23216622. verified
- Thomé U, Batista LA, Rocha RP, et al. The important role of hemispherotomy for Rasmussen encephalitis: clinical and functional outcomes. Pediatr Neurol 2024;150:82–90. doi:10.1016/j.pediatrneurol.2023.10.016. PMID 37992429. verified
Verification (2026-11-17):
- Each reference's authors, title, journal, year, volume, pages, DOI and PMID were checked on PubMed. Numbers were checked against the PubMed abstracts.
Caveats:
- Reference 1's abstract does not list the criteria themselves. The itemized features, MRI findings and biopsy findings are standard teaching, and should be checked against the reference 1 full text.
- The following are also standard teaching, not drawn from the cited abstracts:
- epilepsia partialis continua as a frequent feature;
- the T-cell mechanism;
- the timing trade-offs;
- the role of immunotherapy in the dominant hemisphere.
- All surgical data are retrospective.
- The figure is an original schematic.